Landmark Data in Intermediate Pulmonary Embolism HI-PEITHO and Clinical Implications
This first section reviewed the results of the multicentre HI-PEITHO randomised controlled trial in intermediate-risk pulmonary embolism.
Intermediate-risk pulmonary embolism remains a challenge in acute cardiovascular care, with important questions around risk stratification, early deterioration and when to escalate treatment.
This webinar brought together an international expert faculty to examine the landmark HI-PEITHO trial, delivering new Level-1 evidence in intermediate-risk PE and exploring what these findings mean for contemporary practice.
The session reviewed the randomised data and its implications for treatment pathways, patient monitoring and multidisciplinary decision-making.
The programme featured a detailed review of the multicentre HI-PEITHO study results, followed by practical insight into the use of the NEWS score to identify clinical deterioration and support objective patient assessment.
Faculty also discussed how these findings may be implemented in real-world settings, including the intensive care perspective and key operational considerations for hospitals managing acute PE.
The webinar concluded with an expert audience Q&A, addressing how this new Level-1 evidence may influence local protocols and patient care.
Learning Objectives
- Review the Design, Key Findings and Clinical Relevance of the HI-PEITHO Trial in Intermediate-Risk Pulmonary Embolism
- Assess How New Randomised Evidence May Inform Treatment Escalation Strategies in Intermediate-Risk PE
- Apply the NEWS score to support identification of early clinical deterioration in patients with acute PE
- Evaluate intensive care and hospital operational considerations for implementing evidence-based PE protocols
Target Audience
- Interventional Cardiologists
- Non-Invasive Cardiologists
- Emergency Medicine Physicians
- Nurses and Primary Care Providers
More from this programme
Part 1
Webinar Welcome & Results of the Multicenter RCT for Intermediate Pulmonary Embolism: HI-PEITHO
This first section reviewed the results of the multicentre HI-PEITHO randomised controlled trial in intermediate-risk pulmonary embolism.
Part 2
The Use of the NEWS Score in Pulmonary Embolism – Validation From the HI-PEITHO Results
This second chapter explored the use of the NEWS score in patients with pulmonary embolism, drawing on validation from the HI-PEITHO results.
Part 3
Implementation of the HI-PEITHO Results – The ICU Perspective
This third chapter explored the implementation of the HI-PEITHO results from an intensive care perspective.
Part 4
Audience Q&A
This final chapter featured an expert audience Q&A, addressing key questions raised during the webinar.
| 1 session | |
| Audience Q&A | Watch now |
Faculty Biographies
Erik Klok
Leiden University Medical Center, Leiden, NL
Erik Klok is Professor of Medicine and an internist specialising in vascular medicine at Leiden University Medical Center, Leiden, the Netherlands. His research focuses on venous thromboembolism, including diagnostic strategies, risk prediction, treatment and long-term complications. Erik Klok is also involved in studies aiming to improve care for patients with acute pulmonary embolism, including those at risk of haemodynamic deterioration.
Lukas Hobohm
Dr Lukas Hobohm is a cardiologist and thrombosis specialist with expertise in pulmonary embolism, venous thromboembolism and acute cardiovascular care. He is recognised for his research in PE risk stratification, outcomes and interventional management, and regularly contributes to international education and evidence-based clinical discussions.
Melanie Ferreira
Dr Melanie Ferreira is an internal medicine specialist based in Lisbon, Portugal, with clinical and academic interests in pulmonary vascular disease, venous thromboembolism and acute pulmonary embolism care. She is affiliated with Unidade Local de Saúde São José and has previously served at Hospital Garcia de Orta. She is also coordinator of the Portuguese Internal Medicine Society’s Pulmonary Vascular Disease and Venous Thromboembolism Group, where her work focuses on education, multidisciplinary collaboration and advancing clinical practice in this field.
Comments